Quick Answer
Kyverna Therapeutics, Inc. reported R&D Expense of $133.72 million for fiscal year 2025.
Kyverna Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $133.72M | +18.9% |
| 2024 | $112.47M | +125.3% |
| 2023 | $49.92M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.46M | +4.3% | -15.0% |
| June 30, 2025 | $35.82M | +31.1% | -4.3% |
| March 31, 2025 | $37.43M | +66.5% | +28.2% |
| September 30, 2024 | $29.19M | +114.0% | +6.9% |
| June 30, 2024 | $27.32M | +162.6% | +21.6% |
| March 31, 2024 | $22.48M | +158.0% | +64.7% |
| September 30, 2023 | $13.64M | — | +31.1% |
| June 30, 2023 | $10.40M | — | +19.4% |
- Kyverna Therapeutics, Inc. showed an increase of +18.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s r&d expense has grown by 167.9% (from $49.92 million to $133.72 million).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: